This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Fibroids and oral contraceptive pill

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • evidence from Chiaffarino et al suggests at least a lack of association between the combined oral contraceptive and the risk of developing fibroids and a possible protective effect with long-term use

  • Chiaffarino undertook a case-control study in Milan - cases were collected from referrals for surgery because of menorrhagia or echographic signs of large myomas; controls came from a similar catchment area admitted for acute non-gynaecological, hormonal or neoplastic reasons (controls with a confirmed or suspected history of uterine fibroids were excluded)

  • the study revealed that women taking the pill had a significantly lower risk of fibroids which decreased with duration of use; women who had previously or never taken the pill had similar rates of development of fibroids; however pill use for less than a year showed an increased chance of fibroids; there was no association between risk of fibroids and time since stopping oral contraceptive use

A more recent study suggests that fibroids study should not be considered a contra-indication for OCs use.


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.